SLC5A2 and type 2 diabetes mellitus: The reduced 1,5‐AG plasma levels in patients with T2DM with stable glucose‐lowering background therapy under additional administration of empagliflozin is in accordance with findings of a recent study by Kappel et al., suggesting an inhibited reabsorption of 1,5‐AG due to SGLT2 inhibition, independent of blood glucose levels [30].